November 17, 2026
Elite Diagnostic Limited (ELITE)
Unaudited financials for the first quarter ended September 30, 2026:
Elite Diagnostic Limited (ELITE) reported a 1% increase in revenue, totalling $219.24 million for the first quarter ended September 30, 2026, compared to $217.30 million in the corresponding three months last year.
Year to date, direct cost amounted to $53.09 million (2025: $51.34 million), representing a 3% increase year-over-year. Consequently, gross profit was essentially flat, rising by 0.11% to $166.15 million, compared to $165.96 million for the first quarter ended September 30, 2025. The gross profit margin compressed to 75.79% from 76.38%.
Administrative Expenses increased by 12%, closing at $112.12 million (2025: $100.01 million), a rise of $12.11 million that is more than six times the $1.94 million increase in revenue, while Depreciation increased by 2%, moving from $44.31 million in 2025 to $45.12 million for the three months. No impairment allowance was recorded in either period. Total operating expenses therefore amounted to $157.23 million, a 9% increase relative to $144.32 million reported in 2025. As a result, Operating Profit for the first quarter amounted to $8.92 million, a 59% decrease relative to $21.64 million reported in 2025, with the operating margin narrowing to 4.07% from 9.96%.
Finance Cost totalled $16.53 million, a 56% increase from the corresponding period last year (2025: $10.61 million). Foreign Exchange Gain for the three months amounted to $1.43 million, an 83% increase compared to $0.78 million reported in 2025, while other income amounted to $94,000 (2025: $633,000).
The company recorded a Loss Before Tax of $6.10 million for the first quarter ended September 30, 2026, a swing from the profit before tax of $12.44 million reported in 2025. Notwithstanding the pre-tax loss, a tax charge of $0.55 million was incurred in the period (2025: $0.35 million, as restated). Net Loss for the three months therefore amounted to $6.65 million, compared to a net profit of $12.09 million reported in 2025. The directors attribute the loss to equipment downtime in the Kingston operations and to expenditure associated with the relocation from Holborn Road to Winchester Road.
Consequently, Earnings Per Share for the three months amounted to LPS: $0.019 (2025: EPS: $0.034). The twelve-month trailing EPS was $0.03, and the number of shares used in these calculations was 353,400,000. Notably, ELITE’s stock price closed the trading period on November 17, 2026, at a price of $1.89 with a corresponding P/E ratio of 75.40x.
Balance Sheet Highlights
The company’s assets totalled $1.29 billion (2025: $1.22 billion). The movement in total assets was mainly attributable to a 48% increase in ‘Property, plant and equipment’ amounting to $1.00 billion (2025: $677.41 million), reflecting the acquisition of the property at 1 Winchester Road, Kingston 10, which was offset by a 69% decline in ‘Cash and cash equivalents’ amounting to $68.14 million (2025: $217.06 million) and the reclassification of the $122.92 million ‘Deposit on equipment’ that was held in current assets a year earlier (2026: $21.78 million, now non-current). Total liabilities rose 9% to $726.83 million (2025: $667.09 million), as long-term loans of $212.81 million (nil in 2025) more than offset a reduction in the unsecured corporate bond to $374.22 million (2025: $391.25 million).
Shareholders’ equity was $563.96 million (2025: $555.10 million), representing a book value per share of $1.60 (2025: $1.57), and the closing price of $1.89 equates to a price to book ratio of 1.18x.

Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.